

## IL1RAP is related to CML clinical phase

**Table S1.** The detailed information of CML patients

Sample	Phase	Patient	Sex	Age	Treatment	Blood test (10 <sup>9</sup> /L)					BCR-ABL	IL1RAP + cell%			Karyotype
						WBC	NE	LY	RBC	PLT		CD34+	CD34+CD38-	CD34+CD38+	
PB	CP	1	M	40	hydroxyurea	91.01	0	8.8	4.99	217	+	0	7.09	0	T (9; 22) (q34; q11)
PB	CP	2	M	40	hydroxyurea	15.21	9.33	3.3	4.64	220	No Det.	0	16.13	3.97	No Det.
PB	CP	3	M	40	hydroxyurea	3.61	1.64	1.6	4.02	127	No Det.	10.84	24.73	53.38	No Det.
PB	CP	4	F	29	hydroxyurea	1.67	0.44	0.7	2.93	416	+	32.59	49.17	77.98	No Det.
PB	CP	5	F	29	hydroxyurea	4.58	1.77	1	3.05	1303	+	51.31	32.48	95.65	No Det.
PB	CP	6	M	49	hydroxyurea	208.29	0	0	3.01	340	No Det.	36.82	40.32	38.59	No Det.
PB	CP	7	M	50	TKI	3.7	2.93	0.7	2.32	98	No Det.	11.86	24.02	39.44	No Det.
PB	CP	8	M	24	hydroxyurea	56.48	-	-	3.87	124	No Det.	70.83	87.28	84.4	No Det.
PB	CP	9	M	25	HSCT	3.91	2.45	1.2	3.18	89	+	7.63	56.47	82.74	46, XY, t (9; 22)
PB	CP	10	M	48	hydroxyurea	19.34	0	0	3.59	491	No Det.	51.87	49.65	68.34	No Det.
PB	CP	11	M	58	hydroxyurea	152.85	-	-	2.97	489	+	85.89	23.68	85.3	46, XY, t (9; 22) [5]
PB	CP	12	F	58	hydroxyurea	181.84	0	0	3.26	702	-	53.36	39.15	45.1	46, XX [5]
PB	CP	13	M	22	hydroxyurea	18.59	13.08	3.2	5.09	1463	No Det.	26.19	27.63	53.14	No Det.
PB	CP	14	M	22	TKI	9.89	6.37	2.3	4.78	889	+	9.45	17.57	69.44	46, XY, t (9; 22) [5]
PB	CP	15	M	60	IFN	61.93	0	3.8	6.06	406	No Det.	67.57	86.25	74.81	46, XX [6]
PB	CP	16	M	60	hydroxyurea	20.67	18.17	1.5	5.6	115	No Det.	44.85	81.68	66.51	No Det.
PB	CP	17	F	43	HSCT	-	-	-	-	-	No Det.	5.43	14.97	82.85	No Det.
PB	CP	18	M	39	hydroxyurea	202.13	0	0	3.69	182	+	63.91	79.25	78.12	46, XY, t (9; 22) [10]
PB	CP	19	F	34	HSCT	3.17	1.89	0.8	2.7	89	No Det.	3.37	4.96	35.47	No Det.
PB	CP	20	F	34	HSCT	6.56	4.36	1.5	3.31	185	-	2.53	0.56	93.94	46, XY [20]
PB	CP	21	M	51	TKI	4.15	2.16	1.6	4.19	137	+	1.23	3.34	66.48	46, XX [11]
PB	CP	22	F	50	hydroxyurea	68.99	60.5	3.6	2.79	1159	+	21.14	18.04	45.87	No Det.
PB	CP	23	M	34	TKI	4.84	2.06	2.2	4.23	137	No Det.	28.4	67.83	50.24	46, XY, t (9; 22) (q34; q11) [2]/46, XY [8]
PB	CP	24	M	68	TKI	4.28	1.84	1.9	3.53	144	+	27.06	68.19	57.68	No Det.
PB	CP	25	M	47	hydroxyurea	8.47	5.68	2.3	4.08	191	No Det.	0	4.48	90.61	46, XY, t (9; 22) (q34; q11) [2]
PB	CP	26	M	41	hydroxyurea	29.47	26.41	1.4	4.11	385	+	9.16	25.66	67.56	46, XY, t (9; 22) [6]
PB	CP	27	F	38	hydroxyurea	25.92	19.16	3.2	3.59	1158	No Det.	10	14	53.57	No Det.
PB	CP	28	F	24	hydroxyurea	52.08	43.95	5.5	4.24	592	+	10.12	9.81	37.72	46, XX, t (9; 22) [10]
PB	CP	29	M	58	hydroxyurea	365.46	-	-	3.26	227	No Det.	27.95	30.57	7.31	46, XY, t (9; 22) (q34; q11) [10]
PB	CP	30	M	65	IFN and hydroxyurea	82.13	-	-	3.68	510	-	65.05	46.58	36.04	No Det.
PB	CP	31	M	22	TKI	249.6	-	-	2.67	88	+	40.4	38.79	60.32	No Det.
PB	CP	32	M	22	TKI	5.99	4.61	1.1	4.03	176	No Det.	1.04	27.47	81.92	No Det.
PB	CP	33	M	24	TKI	6	3.01	2.6	4.54	158	No Det.	1.64	0.27	38.88	No Det.
PB	CP	34	M	42	hydroxyurea	130.79	-	6.1	3.91	364	+	15.65	59.2	78.89	46, XY, t (9; 22) [10]
PB	CP	35	M	37	TKI	4.44	2.93	1	3.27	154	No Det.	30	38.64	78.83	No Det.
PB	CP	36	M	35	TKI	2.02	1.22	0.5	3.13	56	No Det.	1.72	3.01	35.86	No Det.
PB	CP	37	F	48	hydroxyurea	357.77	□	□	2.7	454	+	65.72	27.59	21.16	46, XX, t (9; 22) (q34; q11) [10]

## IL1RAP is related to CML clinical phase

PB	CP	38	M	51	TKI	6.33	3.53	2.3	4.44	178	-	0.84	6.89	26.42	46, XY, [3]
PB	CP	39	M	72	hydroxyurea	118.03	-	-	3.99	427	+	59.2	29.13	33.21	46, XY, t (9; 22) (q34; q11) [10]
PB	CP	40	F	68	hydroxyurea	4.3	3.3	0.8	0.98	37	-	1.43	8.5	17.84	46, XX [20]
PB	CP	41	F	88	hydroxyurea	80.11	-	-	3	324	-	48.72	39.22	66.58	46, XX, add (5) (q35), del (6) (p22), del (3) (?q14) [8]/46XX [2]
PB	CP	42	F	40	hydroxyurea	82.53	72.98	4.5	3.88	1041	+	51.18	38.44	53.99	No Det.
PB	CP	43	F	44	leukapheresis	197.65	-	-	3.38	608	+	51.92	27.89	61.64	46, XX, t (9; 22) (q34; q11) [10]
PB	CP	44	F	11	TKI	6.87	3.15	3.3	4	165	+	7.39	17.63	83.95	46, XX, t (9; 22) (q34; q11) [4]/46, XX [16]
PB	CP	45	F	46	hydroxyurea	505.6	0	0	1.74	314	+	21.54	90.95	1.47	No Det.
PB	CP	46	M	8	HSCT	5.6	3.66	1.4	3.46	240	No Det.	24.62	2.9	4.04	No Det.
PB	CP	47	F	28	TKI	17.9	0	2.9	1.79	276	No Det.	14.49	10.54	37.51	No Det.
PB	CP	48	M	22	IFN	4.76	2.96	1.4	4.55	213	+	9.87	10.31	39.71	46, XY, t (9; 22) [6]/46, XY [16]
PB	CP	49	M	50	leukapheresis	7.82	6.77	0.5	3.6	334	+	0.78	6.7	84.29	46, XY, der (1) t (1; 8) (q43; q13), der (3), del (6) (p23), del (8) (q11), t (9; 22) [3]
PB	CP	50	M	58	hydroxyurea	146.4	0	10.1	2.73	1791	No Det.	19.51	11.32	82.77	No Det.
PB	CP	51	F	63	hydroxyurea	4.8	3.61	0.7	3.4	280	No Det.	2.21	10.82	55.95	No Det.
PB	AP	52	M	50	TKI	23.6	0	0	3.31	92	+	57.1	88.11	30.39	No Det.
PB	AP	53	M	31	TKI	13.29	-	-	2.96	163	+	95.82	95	98.4	45, XY, -7, t (9; 22) [10]
PB	AP	54	M	51	TKI	29.25	-	-	0.85	785	+	62.12	71.86	93.05	46, XY, t (9; 22) (q34; q11) [8]/46; idem, -1, der (11) t (1; 11) (p32; q23), del (12) (q21), +mar [2]
PB	AP	55	M	23	TKI	24.28	□	□	5.57	22	+	96.55	82.23	85.26	No Det.
PB	AP	56	M	23	TKI	5.87	1.39	3.9	5.31	12	No Det.	48.31	55.93	41.02	No Det.
PB	AP	57	M	25	TKI	321.89	0	0	2.04	17	No Det.	95.67	92.11	92.77	No Det.
PB	AP	58	M	52	hydroxyurea	66.8	0	0	1.88	289	+	93.3	93.64	93.08	No Det.
PB	BP	59	M	31	TKI	12.24	0	0	2	84	No Det.	95.85	97.13	99.53	No Det.
PB	BP	60	M	23	TKI	10.76	0	0	3.69	67	+	84.73	91.79	75.9	No Det.
PB	BP	61	M	55	TKI	9.97	-	-	1.57	321	+	80.87	73.71	74.97	46, XY, t (3; 3) (q21; q26), -7, t (9; 22), +mar [inc4]
PB	BP	62	M	55	TKI	5.19	0.91	2.4	2.37	21	+	36.67	30.49	8.42	No Det.
PB	BP	63	M	34	anti-infective treatment	52.45	0	0	2.37	20	+	96.52	86.02	99.65	54, XY, +Y, +4, +8 t (9; 22), +15, +19, +19, +21, +ph [CP10]
PB	BP	64	M	18	TKI	122.45	-	-	2.78	14	+	20.78	10.83	10.17	45, XY, dic (7; 9) (p11; p11), t (9; 22) [6]/46, idem, +ph (4)
PB	BP	65	F	26	hydroxyurea	250.8	□	□	3.62	309	No Det.	1.3	88.36	16.41	No Det.
BM	CP	5	F	29	hydroxyurea	4.58	1.77	1	3.05	1303	No Det.	27.68	21.14	85.17	No Det.
BM	CP	9	M	25	HSCT	3.91	2.45	1.2	3.18	89	+	3.23	21.91	4.12	46, XY, t (9; 22)
BM	CP	10	M	48	hydroxyurea	106.57	0	0	3.52	307	No Det.	79.88	24.84	84.26	46, XY, t (9; 22) [1]
BM	CP	18	M	39	hydroxyurea	202.13	0	0	3.69	182	+	40.15	64.66	83.29	46, XY, t (9; 22) [10]
BM	CP	22	F	50	hydroxyurea	68.99	60.5	3.6	2.79	1159	+	12.43	13.66	22.09	No Det.
BM	CP	25	M	41	hydroxyurea	29.47	26.41	1.4	4.11	385	+	15.3	18.44	26.51	46, XY, t (9; 22) [6]

### IL1RAP is related to CML clinical phase

BM	CP	30	M	65	IFN and hydroxyurea	82.13	-	-	3.68	510	-	54.55	65.36	36.79	No Det.
BM	CP	66	M	24	TKI	4.4	2.32	1.8	4.35	150	No Det.	10.54	23.79	-35.28	46, XY, t (9; 22) [8]/46, XY [2]
BM	CP	33	M	24	TKI	6	3.01	2.6	4.54	158	No Det.	4.55	12.66	45.11	No Det.
BM	CP	34	M	42	hydroxyurea	130.79	-	6.1	3.91	364	+	33.06	53.24	62.24	46, XY, t (9; 22) [10]
BM	CP	35	M	37	TKI	4.44	2.93	1	3.27	154	No Det.	19.96	21.35	35.08	No Det.
BM	CP	37	F	48	hydroxyurea	357.77	-	-	2.7	454	+	66.55	8.71	16.89	46, XX, t (9; 22) (q34; q11) [10]
BM	CP	39	M	72	hydroxyurea	118.03	-	-	3.99	427	+	54.2	20.92	34.5	46, XY, t (9; 22) (q34; q11) [10]
BM	CP	40	F	68	hydroxyurea	4.3	3.3	0.8	0.98	37	-	2.9	12.26	74.89	46, XX [20]
BM	CP	42	F	40	hydroxyurea	82.53	72.98	4.5	3.88	1041	+	25.13	23.07	45.46	No Det.
BM	CP	51	F	63	hydroxyurea	4.8	3.61	0.7	3.4	280	□	4.09	9.13	48.86	No Det.
BM	CP	48	M	22	IFN	4.76	2.96	1.4	4.55	213	+	4.23	13.01	5.41	46,XY,t (9; 22) [6]/46, XY [16]
BM	CP	49	M	50	leukapheresis	7.82	6.77	0.5	3.6	334	+	14.45	16.45	18.49	46, XY, der (1) t (1; 8) (q43; q13), der (3), del (6) (p23), del (8) (q11), t (9; 22) [3]
BM	CP	50	M	58	hydroxyurea	146.4	0	10.1	2.73	1791	No Det.	36.72	32.73	47.68	No Det.
BM	AP	67	M	50	TKI	5.35	0	0	2.49	53	No Det.	67.07	76.74	83.38	No Det.
BM	BP	63	M	34	anti-infective treatment	15.08	-	-	2.79	34	+	98.29	97.41	99.51	54, XY, +Y, +4, +8, t (9; 22), +15, +19, +19, +21, +ph [CP10]
BM	BP	65	F	26	hydroxyurea	250.8	-	-	3.62	309	No Det.	73.41	65.89	38.28	No Det.